ciprofloxacin has been researched along with Bronchitis in 45 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Bronchitis: Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A multinational, multicentre, randomized, prospective, parallel-group study compared treatment with ciprofloxacin administered as an oral suspension (500 mg twice daily for 7 days) with co-amoxiclav tablets (625 mg three times daily for 7 days) in patients suffering from acute exacerbations of chronic bronchitis (AECB)." | 9.09 | The efficacy and safety of a new ciprofloxacin suspension compared with co-amoxiclav tablets in the treatment of acute exacerbations of chronic bronchitis. ( Berrisoul, F; Kearsley, N; Kubin, R; Kuss, A; Read, RC; Torres, A, 1999) |
| "To undertake a 1-year prospective economic evaluation of ciprofloxacin compared with usual antibacterial care (any antibacterial other than a quinolone) for the treatment of acute exacerbations of chronic bronchitis (AECB) in adults presenting with a type I or type II AECB." | 9.09 | Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. ( Grossman, R; La Forge, J; Lampron, N; Mukherjee, J; Torrance, G; Vaughan, D; Walker, V, 1999) |
| "9) suffering from bacterial exacerbation of chronic bronchitis have been randomly treated: 79 with co-amoxiclav (amoxicillin 875 mg+clavulanic acid 125 mg) twice daily, 69 with cefixime (400 mg) once daily, and 70 with ciprofloxacin (500 mg) twice daily for an average period of 10 days." | 9.08 | Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis. ( Beghi, GF; Casalini, A; Cazzola, M; Consigli, GF; Fiorentini, F; Giura, R; Madonini, V; Paizis, G; Tonna, M; Vinciguerra, A, 1995) |
| "To evaluate the costs, consequences, effectiveness, and safety of ciprofloxacin vs standard antibiotic care in patients with an initial acute exacerbation of chronic bronchitis (AECB) as well as recurrent AECBs over a 1-year period." | 9.08 | A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group. ( Cook, R; Eastwood, C; Grossman, R; LaForge, J; Lampron, N; Mukherjee, J; Vaughan, D, 1998) |
| "A randomized, prospective, double-blind, double-dummy, multicenter study investigated the efficacy and safety of 10 days of oral therapy with grepafloxacin at 400 mg once daily, grepafloxacin at 600 mg once daily, or ciprofloxacin at 500 mg twice daily in 624 patients with acute bacterial exacerbations of chronic bronchitis." | 9.08 | Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily. ( Breisch, S; Chodosh, S; Lakshminarayan, S; Swarz, H, 1998) |
| "In a prospective, multicenter, double-blind study, the interval to clinical relapse in patients with acute bacterial exacerbations of chronic bronchitis from whom a pretherapy pathogen was isolated was compared following treatment with ciprofloxacin or cefuroxime axetil." | 9.08 | Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. ( Aneiro, L; Chodosh, S; Drehobl, M; Farkas, S; Kowalsky, S; McCarty, J; Shan, M; Tosiello, R, 1998) |
| "In this prospective, multicenter, double-blind study, the efficacy of ciprofloxacin was compared with that of clarithromycin as therapy for patients with acute bacterial exacerbations of chronic bronchitis (ABECB) from whom a pretherapy pathogen was isolated; the efficacy was measured by the infection-free interval." | 9.08 | Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. ( Anzueto, A; Barkman, HW; Chodosh, S; Kowalsky, S; Moesker, H; Schreurs, A; Shan, M; Siami, G; Stack, T, 1998) |
| "This investigation compared the efficacy of oral formulations of amoxycillin/clavulanate and ciprofloxacin in acute exacerbations of chronic bronchitis." | 9.06 | Controlled prospective study of oral amoxycillin/clavulanate vs ciprofloxacin in acute exacerbations of chronic bronchitis. ( Ritzerfeld, W; Schmidt, EW; Ulmer, WT; Voss, E; Zimmermann, I, 1989) |
| " Following the establishment of a teaching Extended-Care Nursing Home Program, which facilitated the early diagnosis and therapy of bronchopulmonary infections, a comparative trial of oral ciprofloxacin and intramuscular cefamandole was initiated in elderly patients with lower respiratory tract infections." | 9.06 | Prospective study of lower respiratory tract infections in an extended-care nursing home program: potential role of oral ciprofloxacin. ( Breitenbucher, R; Davies, S; Gruninger, R; Guay, DR; Logan, G; Obaid, S; Peterson, PK; Stein, D, 1988) |
| " We report a case of acute interstitial nephritis confirmed by renal biopsy that developed in a patient within days of starting ciprofloxacin therapy." | 8.78 | Ciprofloxacin-induced acute interstitial nephritis. ( Bailey, JR; Philbrick, JT; Trott, SA, 1992) |
| "In a retrospective study, the clinical and microbiological efficacy of amoxycillin-clavulanic acid and ciprofloxacin were evaluated in outpatients observed within the previous year who were affected by acute purulent exacerbations of chronic bronchitis." | 7.68 | Comparative clinical and microbiological study of amoxycillin-clavulanic acid and ciprofloxacin in acute purulent exacerbations of chronic bronchitis. ( Beghi, G; Caratozzolo, O; Legnani, D; Lombardo, VM; Negretto, GG, 1992) |
| "Eighty hospital patients with acute purulent exacerbations of chronic bronchitis associated with Haemophilus influenzae, Streptococcus pneumoniae, Branhamella catarrhalis or Pseudomonas aeruginosa were treated with ciprofloxacin." | 7.67 | Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. ( Baur, C; Davies, BI; Maesen, FP, 1986) |
| "Thirty four patients with acute purulent exacerbations of chronic bronchitis were treated with 500 mg ciprofloxacin twice daily, orally, for ten days." | 7.67 | Ciprofloxacin in acute exacerbations of chronic bronchitis. ( Hoogkamp-Korstanje, JA; Klein, SJ, 1986) |
| "Thirty four patients with acute purulent exacerbations of chronic bronchitis were treated with 500 mg ciprofloxacin twice daily, orally, for ten days." | 7.67 | Treatment of acute exacerbations of chronic bronchitis with ciprofloxacin. ( Hoogkamp-Korstanje, JA; Klein, SJ, 1987) |
| "To examine the pharmacokinetics of ciprofloxacin and fleroxacin in plasma and sputum of patients with an acute exacerbation of chronic bronchitis or bronchiectasis following the first dose and again during the third day of treatment." | 5.09 | The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing. ( Begg, EJ; Buttimore, RC; Graham, GG; Neill, AM; Robson, RA; Saunders, DA; Town, GI, 2000) |
| "To undertake a 1-year prospective economic evaluation of ciprofloxacin compared with usual antibacterial care (any antibacterial other than a quinolone) for the treatment of acute exacerbations of chronic bronchitis (AECB) in adults presenting with a type I or type II AECB." | 5.09 | Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. ( Grossman, R; La Forge, J; Lampron, N; Mukherjee, J; Torrance, G; Vaughan, D; Walker, V, 1999) |
| "A multinational, multicentre, randomized, prospective, parallel-group study compared treatment with ciprofloxacin administered as an oral suspension (500 mg twice daily for 7 days) with co-amoxiclav tablets (625 mg three times daily for 7 days) in patients suffering from acute exacerbations of chronic bronchitis (AECB)." | 5.09 | The efficacy and safety of a new ciprofloxacin suspension compared with co-amoxiclav tablets in the treatment of acute exacerbations of chronic bronchitis. ( Berrisoul, F; Kearsley, N; Kubin, R; Kuss, A; Read, RC; Torres, A, 1999) |
| "In this prospective, multicenter, double-blind study, the efficacy of ciprofloxacin was compared with that of clarithromycin as therapy for patients with acute bacterial exacerbations of chronic bronchitis (ABECB) from whom a pretherapy pathogen was isolated; the efficacy was measured by the infection-free interval." | 5.08 | Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. ( Anzueto, A; Barkman, HW; Chodosh, S; Kowalsky, S; Moesker, H; Schreurs, A; Shan, M; Siami, G; Stack, T, 1998) |
| "9) suffering from bacterial exacerbation of chronic bronchitis have been randomly treated: 79 with co-amoxiclav (amoxicillin 875 mg+clavulanic acid 125 mg) twice daily, 69 with cefixime (400 mg) once daily, and 70 with ciprofloxacin (500 mg) twice daily for an average period of 10 days." | 5.08 | Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis. ( Beghi, GF; Casalini, A; Cazzola, M; Consigli, GF; Fiorentini, F; Giura, R; Madonini, V; Paizis, G; Tonna, M; Vinciguerra, A, 1995) |
| "The efficacy of ciprofloxacin was studied in the treatment of 22 patients with hospital infection of the lower respiratory tract: 10 patients with nosocomial pneumonia, 8 with exacerbation of chronic obstructive bronchitis, 3 with exacerbation of mucoviscidosis and 1 with bronchiectasis." | 5.08 | [Effectiveness of ciprofloxacin in the treatment of hospital infections of the lower respiratory tract]. ( Avdeev, SN; Belevskiĭ, AS; Chuchalin, AG; Novikov, IuK, 1997) |
| "To evaluate the costs, consequences, effectiveness, and safety of ciprofloxacin vs standard antibiotic care in patients with an initial acute exacerbation of chronic bronchitis (AECB) as well as recurrent AECBs over a 1-year period." | 5.08 | A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group. ( Cook, R; Eastwood, C; Grossman, R; LaForge, J; Lampron, N; Mukherjee, J; Vaughan, D, 1998) |
| "A randomized, prospective, double-blind, double-dummy, multicenter study investigated the efficacy and safety of 10 days of oral therapy with grepafloxacin at 400 mg once daily, grepafloxacin at 600 mg once daily, or ciprofloxacin at 500 mg twice daily in 624 patients with acute bacterial exacerbations of chronic bronchitis." | 5.08 | Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily. ( Breisch, S; Chodosh, S; Lakshminarayan, S; Swarz, H, 1998) |
| "In a prospective, multicenter, double-blind study, the interval to clinical relapse in patients with acute bacterial exacerbations of chronic bronchitis from whom a pretherapy pathogen was isolated was compared following treatment with ciprofloxacin or cefuroxime axetil." | 5.08 | Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. ( Aneiro, L; Chodosh, S; Drehobl, M; Farkas, S; Kowalsky, S; McCarty, J; Shan, M; Tosiello, R, 1998) |
| "This investigation compared the efficacy of oral formulations of amoxycillin/clavulanate and ciprofloxacin in acute exacerbations of chronic bronchitis." | 5.06 | Controlled prospective study of oral amoxycillin/clavulanate vs ciprofloxacin in acute exacerbations of chronic bronchitis. ( Ritzerfeld, W; Schmidt, EW; Ulmer, WT; Voss, E; Zimmermann, I, 1989) |
| " Following the establishment of a teaching Extended-Care Nursing Home Program, which facilitated the early diagnosis and therapy of bronchopulmonary infections, a comparative trial of oral ciprofloxacin and intramuscular cefamandole was initiated in elderly patients with lower respiratory tract infections." | 5.06 | Prospective study of lower respiratory tract infections in an extended-care nursing home program: potential role of oral ciprofloxacin. ( Breitenbucher, R; Davies, S; Gruninger, R; Guay, DR; Logan, G; Obaid, S; Peterson, PK; Stein, D, 1988) |
| "Thirty one patients were treated with oral ciprofloxacin for bronchitis with Pseudomonas aeruginosa." | 5.06 | Ciprofloxacin for respiratory tract infection with Pseudomonas aeruginosa. ( Haverkorn, MJ, 1987) |
| " We report a case of acute interstitial nephritis confirmed by renal biopsy that developed in a patient within days of starting ciprofloxacin therapy." | 4.78 | Ciprofloxacin-induced acute interstitial nephritis. ( Bailey, JR; Philbrick, JT; Trott, SA, 1992) |
| "Sixty outpatients at the age of 65 to 75 years with exacerbated chronic bronchitis were treated with antibiotics: amoxycillin/clavulanic acid (20 patients), cefaclor (20 patients) and ciprofloxacin (20 patients)." | 3.69 | [Treatment of lower respiratory tract infections in the elderly]. ( Belousov, IuB; Efremenkova, OV; Komarova, VP; Sokolov, AV; Tishchenkova, IF, 1997) |
| "In a retrospective study, the clinical and microbiological efficacy of amoxycillin-clavulanic acid and ciprofloxacin were evaluated in outpatients observed within the previous year who were affected by acute purulent exacerbations of chronic bronchitis." | 3.68 | Comparative clinical and microbiological study of amoxycillin-clavulanic acid and ciprofloxacin in acute purulent exacerbations of chronic bronchitis. ( Beghi, G; Caratozzolo, O; Legnani, D; Lombardo, VM; Negretto, GG, 1992) |
| "Oral quinolones such as ciprofloxacin are promising agents in the treatment of serious bronchopulmonary infections due to susceptible gram-negative micro-organisms such as Haemophilus influenzae, Branhamella catarrhalis, Klebsiella pneumoniae and even Pseudomonas aeruginosa." | 3.67 | Role of fluoroquinolones in lower respiratory tract infections. ( Vellend, H, 1989) |
| "Eighty hospital patients with acute purulent exacerbations of chronic bronchitis associated with Haemophilus influenzae, Streptococcus pneumoniae, Branhamella catarrhalis or Pseudomonas aeruginosa were treated with ciprofloxacin." | 3.67 | Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. ( Baur, C; Davies, BI; Maesen, FP, 1986) |
| "Thirty four patients with acute purulent exacerbations of chronic bronchitis were treated with 500 mg ciprofloxacin twice daily, orally, for ten days." | 3.67 | Treatment of acute exacerbations of chronic bronchitis with ciprofloxacin. ( Hoogkamp-Korstanje, JA; Klein, SJ, 1987) |
| "Ciprofloxacin therapy was well tolerated; ceftriaxone therapy was discontinued in two patients (8%) due to adverse reactions (intramuscular pain and drug fever)." | 2.67 | A randomized study of ciprofloxacin versus ceftriaxone in the treatment of nursing home-acquired lower respiratory tract infections. ( Gruninger, RP; Guay, DR; Hirata-Dulas, CA; Peterson, PK; Stein, DJ, 1991) |
| "Fifty-two patients with serious respiratory infections were treated with orally administered ciprofloxacin; 42 patients were evaluable for the efficacy analysis and all were evaluable for determining adverse reactions." | 2.66 | Efficacy and safety of oral ciprofloxacin in the treatment of serious respiratory infections. ( Fass, RJ, 1987) |
| "Ciprofloxacin was given twice a day, as 500 mg through a gastric tube or 200 mg intravenously, and both applications led to negative cultures for aerobic Gram-negative bacilli from faeces and throat, except for a few periods of carriage lasting only a few days." | 1.28 | Prophylaxis of respiratory tract infection in patients on artificial respiration. ( Haverkorn, MJ, 1989) |
| " An oral dose of 500 mg every 12 h was administered and both the clinical response and the pharmacokinetic profile were investigated." | 1.27 | Ciprofloxacin: multiple-dose pharmacokinetic and clinical results in patients with hypercrinic bronchopulmonary diseases. ( Braga, PC; Cortelazzi, R; Cosentina, R; Fraschini, F; Odero, A; Salvini, P; Scaglione, F; Scarpazza, G; Trazzi, R, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (35.56) | 18.7374 |
| 1990's | 24 (53.33) | 18.2507 |
| 2000's | 5 (11.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beck, N | 1 |
| Folia, M | 1 |
| Mahy, S | 1 |
| Duvillard, C | 1 |
| Chanteret, C | 1 |
| Lecomte, H | 1 |
| Gazzano, E | 1 |
| Piroth, L | 1 |
| Romanet, P | 1 |
| Shah, P | 1 |
| Brückner, O | 1 |
| Trautmann, M | 1 |
| Tsifansky, MD | 1 |
| Yeo, Y | 1 |
| Evgenov, OV | 1 |
| Bellas, E | 1 |
| Benjamin, J | 1 |
| Kohane, DS | 1 |
| Donaldson, PM | 1 |
| Pallett, AP | 1 |
| Carroll, MP | 1 |
| Houston, S | 1 |
| Nouvet, G | 1 |
| Benmessaoud, K | 1 |
| Cazzola, M | 1 |
| Vinciguerra, A | 1 |
| Beghi, GF | 1 |
| Paizis, G | 1 |
| Giura, R | 1 |
| Madonini, V | 1 |
| Fiorentini, F | 1 |
| Consigli, GF | 1 |
| Tonna, M | 1 |
| Casalini, A | 1 |
| Chuchalin, AG | 1 |
| Novikov, IuK | 1 |
| Avdeev, SN | 1 |
| Belevskiĭ, AS | 1 |
| Grossman, R | 2 |
| Mukherjee, J | 3 |
| Vaughan, D | 3 |
| Eastwood, C | 1 |
| Cook, R | 1 |
| LaForge, J | 1 |
| Lampron, N | 2 |
| Chodosh, S | 5 |
| Lakshminarayan, S | 1 |
| Swarz, H | 1 |
| Breisch, S | 1 |
| Komarova, VP | 1 |
| Belousov, IuB | 1 |
| Sokolov, AV | 1 |
| Tishchenkova, IF | 1 |
| Efremenkova, OV | 1 |
| Ng, ET | 2 |
| Cook, RJ | 2 |
| Zuck, P | 1 |
| McCarty, J | 1 |
| Farkas, S | 1 |
| Drehobl, M | 1 |
| Tosiello, R | 1 |
| Shan, M | 2 |
| Aneiro, L | 1 |
| Kowalsky, S | 2 |
| Schreurs, A | 1 |
| Siami, G | 1 |
| Barkman, HW | 1 |
| Anzueto, A | 2 |
| Moesker, H | 1 |
| Stack, T | 1 |
| Destache, CJ | 1 |
| Dewan, N | 1 |
| O'Donohue, WJ | 1 |
| Campbell, JC | 1 |
| Angelillo, VA | 1 |
| Rizzo, JA | 1 |
| Grossman, RF | 1 |
| Read, RC | 1 |
| Kuss, A | 1 |
| Berrisoul, F | 1 |
| Kearsley, N | 1 |
| Torres, A | 1 |
| Kubin, R | 1 |
| Begg, EJ | 1 |
| Robson, RA | 1 |
| Saunders, DA | 1 |
| Graham, GG | 1 |
| Buttimore, RC | 1 |
| Neill, AM | 1 |
| Town, GI | 1 |
| Torrance, G | 1 |
| Walker, V | 1 |
| La Forge, J | 1 |
| Grassi, C | 1 |
| Salvatori, E | 1 |
| Rosignoli, MT | 1 |
| Dionisio, P | 1 |
| Legnani, D | 1 |
| Lombardo, VM | 1 |
| Negretto, GG | 1 |
| Beghi, G | 1 |
| Caratozzolo, O | 1 |
| Bailey, JR | 1 |
| Trott, SA | 1 |
| Philbrick, JT | 1 |
| Kosmidis, J | 1 |
| Thys, JP | 1 |
| Jacobs, F | 1 |
| Byl, B | 1 |
| Hirata-Dulas, CA | 1 |
| Stein, DJ | 1 |
| Guay, DR | 2 |
| Gruninger, RP | 1 |
| Peterson, PK | 2 |
| Canton, P | 1 |
| Hoen, B | 1 |
| Richet, H | 1 |
| Ravoire, S | 1 |
| Acar, JF | 1 |
| Haverkorn, MJ | 2 |
| Tuck, J | 1 |
| Stottmeier, KD | 1 |
| Pizzuto, D | 1 |
| Schmidt, EW | 1 |
| Zimmermann, I | 1 |
| Ritzerfeld, W | 1 |
| Voss, E | 1 |
| Ulmer, WT | 1 |
| Vellend, H | 1 |
| Davies, BI | 3 |
| Maesen, FP | 3 |
| Teengs, JP | 2 |
| Baur, C | 3 |
| Finch, R | 1 |
| Whitby, M | 1 |
| Craddock, C | 1 |
| Holliday, A | 1 |
| Martin, J | 1 |
| Pilkington, R | 1 |
| Stein, D | 1 |
| Logan, G | 1 |
| Obaid, S | 1 |
| Gruninger, R | 1 |
| Davies, S | 1 |
| Breitenbucher, R | 1 |
| Hoogkamp-Korstanje, JA | 2 |
| Klein, SJ | 2 |
| Fass, RJ | 1 |
| Fraschini, F | 1 |
| Braga, PC | 1 |
| Cosentina, R | 1 |
| Salvini, P | 1 |
| Cortelazzi, R | 1 |
| Scarpazza, G | 1 |
| Scaglione, F | 1 |
| Trazzi, R | 1 |
| Odero, A | 1 |
3 reviews available for ciprofloxacin and Bronchitis
| Article | Year |
|---|---|
Ciprofloxacin-induced acute interstitial nephritis.
Topics: Acute Kidney Injury; Aged; Bronchitis; Ciprofloxacin; Female; Humans; Nephritis, Interstitial | 1992 |
Use of quinolones for the treatment of acute exacerbations of chronic bronchitis.
Topics: Acute Disease; Anti-Infective Agents; Bronchitis; Chronic Disease; Ciprofloxacin; Fluoroquinolones; | 1991 |
Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.
Topics: Anti-Infective Agents; Bronchitis; Ciprofloxacin; Drug Therapy, Combination; Enoxacin; Humans; Oflox | 1991 |
22 trials available for ciprofloxacin and Bronchitis
| Article | Year |
|---|---|
Comparative study of efficacy and safety of ciprofloxacin and cefixime in the treatment of acute exacerbations of chronic bronchitis after first-line treatment failure. French Study Group.
Topics: Aged; Anti-Infective Agents; Bronchitis; Cefixime; Cefotaxime; Chronic Disease; Ciprofloxacin; Drug | 1995 |
Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Amoxicillin-Potassium Clavulanate Combinati | 1995 |
[Effectiveness of ciprofloxacin in the treatment of hospital infections of the lower respiratory tract].
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Infective Agents; Bronchiectasis; Bronchitis; Ch | 1997 |
A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group.
Topics: Adolescent; Adult; Anti-Infective Agents; Bronchitis; Canada; Chronic Disease; Ciprofloxacin; Cost-B | 1998 |
Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Bronch | 1998 |
Modeling two-state disease processes with random effects.
Topics: Anti-Infective Agents; Bronchitis; Chronic Disease; Ciprofloxacin; Epidemiologic Methods; Humans; Li | 1997 |
Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.
Topics: Acute Disease; Adolescent; Adult; Anti-Infective Agents; Bronchitis; Cefuroxime; Cephalosporins; Chr | 1998 |
Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Bronchitis; C | 1998 |
Two-state mixed renewal processes for chronic disease.
Topics: Anti-Infective Agents; Bronchitis; Chronic Disease; Ciprofloxacin; Humans; Likelihood Functions; Mod | 1999 |
The efficacy and safety of a new ciprofloxacin suspension compared with co-amoxiclav tablets in the treatment of acute exacerbations of chronic bronchitis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combina | 1999 |
The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Area Under Curve; Bronchiectasis; Bronchitis; | 2000 |
Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year.
Topics: Adult; Anti-Infective Agents; Bronchitis; Canada; Chronic Disease; Ciprofloxacin; Cost-Benefit Analy | 1999 |
Randomized, double-blind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbations of chronic bronchitis.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bronchitis; Chronic Disease; Ciprofloxacin; Dioxolan | 2002 |
A double-blind study of once-daily temafloxacin in the treatment of bacterial lower respiratory tract infections.
Topics: Adolescent; Adult; Anti-Infective Agents; Bronchitis; Ciprofloxacin; Double-Blind Method; Female; Fl | 1991 |
Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.
Topics: Anti-Infective Agents; Bronchitis; Ciprofloxacin; Drug Therapy, Combination; Enoxacin; Humans; Oflox | 1991 |
A randomized study of ciprofloxacin versus ceftriaxone in the treatment of nursing home-acquired lower respiratory tract infections.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bronchitis; Ceftriaxone; Ciprofloxacin; Cross Infecti | 1991 |
Comparative efficacy of ciprofloxacin versus josamycin in the treatment of acute, recurrent, or exacerbated bronchitis.
Topics: Acute Disease; Bacteria; Bacterial Infections; Bronchitis; Ciprofloxacin; Humans; Josamycin; Microbi | 1989 |
Comparison of ciprofloxacin with ampicillin in acute infectious exacerbations of chronic bronchitis. A double-blind crossover study.
Topics: Adult; Aged; Ampicillin; Bacteria; Bacterial Infections; Bronchitis; Ciprofloxacin; Clinical Trials | 1989 |
Controlled prospective study of oral amoxycillin/clavulanate vs ciprofloxacin in acute exacerbations of chronic bronchitis.
Topics: Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Bronchitis; Chronic Disease; Cipro | 1989 |
Prospective study of lower respiratory tract infections in an extended-care nursing home program: potential role of oral ciprofloxacin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bronchitis; Cefamandole; Ciprofloxacin; Clinical Tria | 1988 |
Ciprofloxacin for respiratory tract infection with Pseudomonas aeruginosa.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bronchitis; Ciprofloxacin; Clinical Trials as Topic; Dru | 1987 |
Efficacy and safety of oral ciprofloxacin in the treatment of serious respiratory infections.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Bronchitis; Ciprofloxacin; Clinical Trials | 1987 |
21 other studies available for ciprofloxacin and Bronchitis
| Article | Year |
|---|---|
[Acute group A beta-hemolytic streptococcus membranous laryngotracheobronchitis in an adult].
Topics: Acute Disease; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; | 2008 |
[Do tendon lesions occur during quinolone administration?].
Topics: Achilles Tendon; Adult; Age Factors; Anti-Infective Agents; Bronchitis; Ciprofloxacin; Enzyme Inhibi | 2003 |
Efficacy and safety in the oral treatment of purulent chest disease and pneumonia with cefixime, ofloxacin, and ciprofloxacin.
Topics: Administration, Oral; Anti-Bacterial Agents; Bronchitis; Cefixime; Ciprofloxacin; Clinical Trials as | 1989 |
Microparticles for inhalational delivery of antipseudomonal antibiotics.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchitis; Ceftazidime; Chromatography, High Pre | 2008 |
Ciprofloxacin in general practice.
Topics: Bronchitis; Ciprofloxacin; Family Practice; Humans; Respiratory Tract Infections | 1994 |
Ciprofloxacin advertising in CMAJ.
Topics: Acute Disease; Advertising; Bronchitis; Chronic Disease; Ciprofloxacin; Drug Resistance, Microbial; | 1993 |
[Management of infection in respiratory tract diseases].
Topics: Amoxicillin; Bacterial Infections; Bronchitis; Bronchopneumonia; Child; Ciprofloxacin; Drug Costs; H | 1995 |
[Treatment of lower respiratory tract infections in the elderly].
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; A | 1997 |
[The role of ciprofloxacin in the treatment of chronic bronchitis].
Topics: Acute Disease; Anti-Infective Agents; Bacterial Infections; Bronchitis; Chronic Disease; Ciprofloxac | 1998 |
Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Bronchitis; Chronic Disease; Ciprofloxacin; Cost- | 1999 |
The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis.
Topics: Acute Disease; Bacterial Infections; Bronchitis; Cefuroxime; Ciprofloxacin; Clarithromycin; Humans; | 1999 |
Comparative clinical and microbiological study of amoxycillin-clavulanic acid and ciprofloxacin in acute purulent exacerbations of chronic bronchitis.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Bacteria | 1992 |
Prophylaxis of respiratory tract infection in patients on artificial respiration.
Topics: Amphotericin B; Bronchitis; Ciprofloxacin; Cross Infection; Drug Therapy, Combination; Feces; Female | 1989 |
Role of fluoroquinolones in lower respiratory tract infections.
Topics: Animals; Anti-Infective Agents; Bronchi; Bronchitis; Ciprofloxacin; Cystic Fibrosis; Gram-Negative B | 1989 |
[New oral quinolone compounds in chronic bronchitis].
Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Cipr | 1986 |
Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Ciprofloxacin; Drug | 1986 |
Clinical evaluation of treatment with ciprofloxacin.
Topics: Abdomen; Abscess; Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Bronchitis; | 1986 |
Quinolone antimicrobial agents in acute exacerbations of chronic bronchitis.
Topics: Anti-Infective Agents; Bacterial Infections; Bronchitis; Ciprofloxacin; Enoxacin; Female; Humans; Ma | 1986 |
Ciprofloxacin in acute exacerbations of chronic bronchitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bronchitis; Ciprofloxacin; Female; Haemophilus influenza | 1986 |
Treatment of acute exacerbations of chronic bronchitis with ciprofloxacin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Bronchitis; Ciprofloxacin; Female; | 1987 |
Ciprofloxacin: multiple-dose pharmacokinetic and clinical results in patients with hypercrinic bronchopulmonary diseases.
Topics: Adult; Aged; Bronchitis; Chronic Disease; Ciprofloxacin; Humans; Kinetics; Lung; Male; Middle Aged; | 1987 |